Jillian Shaw focuses on AI/ML-enabled drug discovery, precision genetic medicines, and platforms targeting genetically defined diseases with high unmet need. As an active Institute Scientist at the Broad Institute of MIT and Harvard, she co-leads the Ladders to Cures Rare Disease Scientific Accelerator — a $22.5M initiative spanning 16 therapeutic programs and 175+ scientists working to identify convergent druggable nodes across genetic disease — giving her direct visibility into the emerging biology, translational bottlenecks, and scientists shaping the next generation of genetic medicines.

Her technical expertise spans massively parallel base editing, Perturb-seq, genome-wide CRISPR screens, and AI/ML-driven variant profiling in iPSC-derived cell lines, with hands-on experience translating these platforms toward druggable target identification and therapeutic programs with broad patient impact across basket indications.

Her scientific training is in synaptic physiology and neurodevelopmental disorders, she earned her PhD from the Zilkha Neurogenetic Institute at USC. Jillian was a postdoctoral research scholar at Stanford, and she received her B.A. with honors from Vassar College. Prior to joining Magnetic in 2022, she consulted for Flagship Pioneering and held a research role at the Cure Alzheimer's Fund, which has distributed over $270M to high-risk, high-reward Alzheimer's research. 

At Magnetic, she supports portfolio companies through scientific diligence, strategic guidance on translational development and platform positioning, and access to a broad network of leading academic researchers and clinicians. Based in Cambridge, MA, she believes the next generation of transformative medicines will emerge from the convergence of functional genomics, AI, and deep mechanistic disease biology and backs founders who share that conviction.